price close busi feb
catalyst beyond
import event come beyond
sinc edit see hit roch crenezumab alzheim
failur see inter part review ipr patent challeng tecfidera multipl
sclerosi highlight under-valued note see
announc pursu opioid withdraw well
announc collabor gene therapi see among
thing separ fda advisori committe bless esketamin nasal
spray treatment-resist depress view outcom sign fda
open novel approach target central nervou system disord
potenti implic lumateperon etc tabl catalyst
come tabl catalyst beyond
nuplazid parkinson diseas psychosi sale outlook key
view issuanc sale outlook nuplazid result
key event stock see initi background could initi
phase pimavanserin inadequ respons major depress disord mdd
includ potenti feedback fda meet
aldr epti migrain prevent biolog licens applic file
eptinezumab intraven approv anti-cgrp biolog subcutan
rimegep file investor focu grow program
expect file new drug applic nda rimegep acut treatment
migrain could report phase data rimegep migrain prevent
could see sever phase start troriluzol program
nv sma type approv vumer ms gi data
gastrointestin toler data vumer nda file vs tecfidera come
competitor nv could get approv spinal muscular atrophi
type partner eisai could initi phase trial earli
alzheim end
ba/pk data proof concept data tnepc
bioavail ba /pk data sublingu dex film agit ad
schizophrenia/bipolar disord preliminari proof-of-concept data
treatment-emerg neuroendocrin prostat cancer tnepc could come
phase data classic close transact
data classic congenit adren hyperplasia expect
zulresso action date phase open-label data bipolar
report action date zulresso iv postpartum
depress see phase open-label part studi data bipolar
depress multipl phase readout could come
canaccord genuiti global capit market group canaccord genuiti group inc cf tsx
recommend opinion express research report accur reflect research analyst person independ object view
compani secur subject report discuss herein
import inform pleas see import disclosur begin page document
potenti meet fda discuss next step pimavanserin mdd
result potenti financi outlook
estim studi complet date phase open-label safeti efficaci
studi pimavanserin
initi phase trial pimavanserin mdd
potenti enrol complet pimavanserin phase
hire chief offic cfo
top-lin result phase trial
estim studi complet date syneurx naben phase trial
estim studi complet date syneurx naben phase trial
potenti initi phase trial epidiolex
potenti start pivot studi evenamid
top-line result allergan rapastinel phase trial
top-line result phase trial minerva mdd
result two phase trial minerva seltorex
patient mdd adjunct therapi
inadequ respons
antidepress
treatment adult
parkinson diseas
inadequ respons
antidepress
adjunct therapi estim primari complet date
adjunct therapi estim studi complet date sep-
announc todd young
employ end elena ridloff serv
suffici least next month per file
potenti approv janssen esketamin nasal spray us fda
axsom meet fda discuss potenti regulatori path forward
potenti updat next step
updat neuralstem
potenti initi phase trial reviva pharmaceut
develop reviva pharmaceut
favor fda advisori committe
meet esketamin pdufa date
parkinson psychosi
form us fda nda plan
meet fda discuss content
potenti next step
result potenti busi updat
ind file
payment teva approv bla eptinezumab
potenti detail long-term data eptinezumab phase studi
hire chief commerci offic
potenti updat eptinezumab subcutan formul
potenti ex-u partner eptinezumab
potenti phase trial initi allergan atogep chronic
potenti data phase trial
later
monoclon antibodi target pituitari
adenyl cyclase-activ
prevent migrain
per aldr european patent settlement global licens
agreement teva
aldr announc ms elisabeth sandov
employ end
expect last per date
result avail year end present
medic confer
launch ramp teva ajovi fremanezumab
launch ramp lilli emgal galcanezumab
track commerci progress amgen/novarti aimovig erenumab
top-line result long term extens phase assess drug signal one
year troriluzol
initi second random control phase trial troriluzol
initi phase trial troriluzol
result potenti busi updat
potenti nda file rimegep
addit data rimegep zydi oral dissolv tablet studi
potenti top-line data phase trial rimegep prevent
potenti enrol complet trial troriluzol sca
complet addit toxicolog phase trial
updat eu strategi rimegep
acut treatment
acut treatment
acut treatment
teva receiv approv price product
aimovig emgal
other monthli
lilli receiv approv price product
aimovig teva ajovi
receiv approv aimovig set
list price per year aimovig
first anti-cgrp product approv fda
approv inject set price
estim primari complet date estim
announc enrol first patient
trial estim studi complet date
receiv feedback ema outlin
sever potenti pathway approv rimegep per
file updat
result long-term safeti studi rimegep
addit data phase studi rimegep studi
addit data proof concept trial anxieti
potenti updat on-going phase trial
potenti nda file allergan ubrogep
later
result phase fortitude- trial reldesemtiv
potenti phase trial initi atogep chronic migrain
potenti nda approv lilli lasmiditan
top-lin result phase studi brainstorm cell
potenti data phase trial
potenti initi phase trial genervon
discuss european medicin agenc path forward
launch ramp teva ajovi fremanezumab
acut treatment
acut treatment
acut treatment
prevent migrain
acut treatment
acut treatment
announc initi result open-label
long-term safeti studi rimegep estim primari
complet date estim studi complet date
upcom scientif meet report
posit top-lin result trial
announc dose first patient
suffici fund oper per file
announc submiss nda
lasmiditan us fda
result avail year end present
medic confer
teva receiv approv price product
aimovig emgal
other monthli
launch ramp lilli emgal galcanezumab
track commerci progress amgen/novarti aimovig erenumab
updat phase trial prana biotech
perform itf pharma tiglutik riluzol oral suspens
initi phase trial ibudilast
conduct addit analys data phase studi neuraltu
potenti accept nda vumer fda
potenti initi confirmatori phase studi
estim studi complet date phase trial
potenti initi phase trial
potenti interim analys phase data aducanumab
potenti initi phase trial
potenti data phase trial
potenti exercis option acquir
sclerosi
potenti approv biosimilar adalimumab us
lilli receiv approv price product
aimovig teva ajovi
receiv approv aimovig set
list price per year aimovig
first anti-cgrp product approv fda
approv inject set price
itf pharma receiv approv expect
launch
receiv posit feedback fda
phase plan ibudilast al
alks/biib announc submiss nda
diroximel fumar regulatori pathway
announc enter
exclus option agreement acquir tm co ltd japan
per slide ioni present date
exercis option ioni develop
commerci base posit interim data readout
phase trial plan add addit cohort
studi potenti support registr
biib/samsung bioepi announc accept
bla adalimumab biosimilar fda
updat phase studi al
potenti five new asset enter clinic
potenti updat phase trial
updat biogen/univers pennsylvania sma gene therapi
updates/furth detail phase studi alzheim
potenti initi phase studi evalu whether earli use
aducanumab prevent delay clinic onset ad
asset acquir
estim studi primari complet date
earn call said fda place ind
clinic hold updat call
eisai/biib present fuller data aaic meet chicago
ctad barcelona sub-group analys
present initi posit top-lin data
studi includ patient evid amyloid
patholog brain without subject cognit
complaint otherwis refer stage fda
draft guidanc treatment earli alzheim diseas
detail data phase trial dapirolizumab pegol upcom medic
potenti updat phase studi healthi volunt
impact roch ocrevu multipl sclerosi franchis
potenti busi develop activity/acquisit
novartis/avexi initi pediatr comer sma type
multi-n trial reach zolgensma
potenti approv launch novartis/avexi zolgensma
potenti approv launch novartis/avexi zolgensma
top-lin result phase studi firdaps
sma type
potenti approv merck kgaa nda mavenclad cladribin
updat potenti submiss market author applic
shanghai greenvalley pharmaceut china
updat on-going pivot trial roch s/ptct
sma type
effect generic copaxon brand ms product
type
earn press releas date biogen
announc acquir alg-
alivegen inc
receiv royalti ocrevu
enrol approxim patient six month
year age qualifi trial
time gene therapi
novarti announc fda accept nda
file prioriti review
novarti initi submiss mid-septemb anticip
complet file end
mild moder
type
fda accept nda merck kgaa mavenclad
potenti path forward sma type
result potenti busi updat
initi phase studi checkpoint inhibitor
initi phase poc studi
potenti data readout bridg bioavail ba pk studi
preliminari data readout phase poc studi
initi registr trial
data phase poc studi
select next clinic candid
interim efficaci analysi axsom phase trial
updat agit patient probabl alzheim diseas
program lumateperon
result potenti busi updat
initi phase clinic trial
type
agit alzheim
diseas schizophrenia
agit alzheim
diseas schizophrenia
agit alzheim
treatment agit
patient probabl
neoadjuv proof mechan trial initi
announc dose first six patient
studi expect enrol healthi adult volunt
expect complet dose patient
mechan action combo trial
last least month
file
announc stop studi
futil
announc posit top-line data phase
studi patient parkinson diseas
initi clinic trial
potenti initi clinic program lumateperon depress
expect top line data phase trial lumateperon
adjunct therapi lithium valproat
updat agit patient probabl alzheim diseas
program lumateperon
potenti data open-label long-term safeti switch studi
opioid substanc
use disord pain
treatment agit
patient probabl
last per file
estim primari complet date estim
announc stop studi
futil
announc favor result
second part open-label safeti switch studi studi
initi phase trial restorbio combin rapalog
parkinson diseas
data readout part open-label portion phase trial
bipolar depress
potenti snda approv allergan vraylar cariprazin
top-line result phase trial minerva mdd
top-line result allergan rapastinel phase trial
initi phase trial acadia pimavanserin adjunct therapi
potenti updat next step
result two phase trial minerva seltorex
patient mdd adjunct therapi
end
announc accept snda fda
pdufa action date may
form us fda nda plan
meet fda discuss content
potenti next step
data phase studi adult
potenti close transact
potenti updat phase trial novel inhibitor
select lead clinic candid friedreich ataxia program
collabor
enrol pivot phase begin vy-aadc
data pivot phase studi phase extens studi
data analysi phase trial t-forc gold ingrezza
long-term data vy-aadc phase cohort
enrol statu phase trial vy-aadc
estim studi complet date phase trial pk/pd spruce
initi larger clinic studi emalex bioscienc ecopipam
potenti initi phase trial obseva linzagolix
initi data first two patient axov scienc phase dose
escal studi sunrise-pd axo-lenti-pd
potenti top-lin data phase trial lundbeck/prexton foliglurax
potenti data myovant/takeda phase trial spirit
potenti initi clinic trial
updat allergan uliprist acet
compani expand studi includ addit
patient optim dose flexibl conveni
month enrol complet month
announc phase t-forc gold
studi valbenazin pediatr tourett syndrom fail
last least next month per file
axon announc patient dose trial
allergan receiv complet respons letter
us fda abl approv uliprist acet
nda current form allergan plan meet fda
discuss comment next step
result potenti busi updat
announc fda extend zulresso
pdufa date final rem
approxim patient recruit
data readout phase target engag studi
data readout phase multipl ascend dose trial
data readout phase singl ascend dose trial
data readout phase target engag studi
data readout phase multipl ascend dose trial
data readout phase singl ascend dose trial
initi phase open-label studi patient essenti
data readout part open-label portion phase trial
bipolar depress
initi phase multipl ascend dose trial patient
earli manifest huntington diseas
plan meet fda develop path
potenti updat addit scientif advic european medicin
agenc brexanolon
top-line result allergan rapastinel phase trial
potenti snda approv allergan vraylar cariprazin
initi phase trial acadia pimavanserin adjunct therapi
top-line result phase trial minerva mdd
data part phase magnolia studi marinu
full data phase amarylli studi
axsom meet fda discuss potenti regulatori path forward
result two phase trial minerva seltorex
patient mdd adjunct therapi
potenti approv janssen esketamin nasal spray us fda
approxim patient recruit
last per file
announc accept snda fda
pdufa action date may
announc posit result part
announc posit result interim
analysi amarylli studi
favor fda advisori committe
meet esketamin pdufa date
result phase trial minerva seltorex patient
insomnia disord monotherapi
updat neuralstem
expect top line data phase trial lumateperon
adjunct therapi lithium valproat
result potenti busi updat
updat formal guidanc receiv scientif advic
work parti sawp european medicin agenc ema
multi-region phase studi
updat clinic develop pathway azeliragon
result potenti busi updat
progress research activ abbvie/tau program compani
identifi five antibodi inclus toward develop
advanc monogen form al toward
enrol pivot phase begin vy-aadc
long-term data vy-aadc phase cohort
initi human studi
enrol statu phase trial vy-aadc
al huntington
estim primari complet date estim
last less month per file
month enrol complet month
last per busi updat call host
initi data first two patient axov scienc phase dose
escal studi sunrise-pd axo-lenti-pd
potenti initi clinic trial
compani report clinicaltri gov canaccord genuiti estim updat
axon announc patient dose trial
potenti meet fda discuss next step pimavanserin mdd
result potenti financi outlook
estim studi complet date phase open-label safeti efficaci
studi pimavanserin
initi phase trial pimavanserin mdd
potenti enrol complet pimavanserin phase
potenti data readout pimavanserin phase studi
estim studi complet date phase open-label trial
initi phase trial trofinetid
potenti enrol complet pimavanserin phase advanc
potenti interim data-readout phase trial harmoni
estim studi complet date phase trial harmoni
potenti result phase trial harmoni pimavanserin
estim studi complet date phase open-label safeti
toler studi pimavanserin
potenti nda file trofinetid
hire chief offic cfo
inadequ respons
antidepress
treatment adult
parkinson diseas
inadequ respons
antidepress
agit aggress
adjunct therapi estim primari complet date
adjunct therapi estim studi complet date sep-
adjunct therapi
studi evalu efficaci safeti approxim
femal age year
adjunct therapi estim studi complet date jun-
adjunct therapi estim primari complet date
announc todd young
employ end elena ridloff serv
suffici least next month per file
request prioriti review base track
design grant lumateperon treatment
announc fda accept nda
lumateperon treatment schizophrenia
favor fda advisori committe
meet esketamin pdufa date
top-lin result phase trial
estim studi complet date syneurx naben phase trial
estim studi complet date syneurx naben phase trial
potenti initi phase trial epidiolex
potenti start pivot studi evenamid
top-line result allergan rapastinel phase trial
top-line result phase trial minerva mdd
top-lin result phase elev trial vistagen
top-lin result phase trial minerva/mitsubishi tanab
potenti file nda schizophrenia
potenti fda advisori committe meet lumateperon
estim studi complet date allergan phase trial
lumateperon fda action date schizophrenia
potenti top-lin data phase star studi newron
estim studi complet date phase debut studi lundbeck lu
estim studi complet date phase trial
estim studi complet date anavex phase trial
estim studi complet date syneurx naben phase trial
result two phase trial minerva seltorex
patient mdd adjunct therapi
potenti approv janssen esketamin nasal spray us fda
axsom meet fda discuss potenti regulatori path forward
potenti updat next step
estim studi complet date phase trial sunovion
estim studi complet date phase studi lundbeck lu
estim studi complet date phase trial mediti pharma mp-
estim studi complet date phase trial astrazeneca
potenti launch rapastinel
updat neuralstem
potenti initi phase trial reviva pharmaceut
develop reviva pharmaceut
compani report clinicaltri gov canaccord genuiti estim updat
form us fda nda plan
meet fda discuss content
potenti next step
parkinson psychosi
adjunct therapi estim primari complet date
result potenti busi updat
ind file
later
payment teva approv bla eptinezumab
initi first-in-human studi
potenti launch eptinezumab
potenti data first-in-human studi
potenti detail long-term data eptinezumab phase studi
hire chief commerci offic
potenti updat eptinezumab subcutan formul
potenti ex-u partner eptinezumab
potenti phase trial initi allergan atogep chronic migrain
potenti data phase trial
estim studi complet date phase trial allergan atogep
daili
estim studi complet date phase trial allergan atogep
daili
launch ramp teva ajovi fremanezumab
end
launch ramp lilli emgal galcanezumab
monoclon antibodi target pituitari
adenyl cyclase-activ
prevent migrain
per aldr european patent settlement global licens
agreement teva
aldr announc ms elisabeth sandov
employ end
expect last per date
result avail year end present
medic confer
teva receiv approv price product
aimovig emgal
other monthli
lilli receiv approv price product
aimovig teva ajovi
receiv approv aimovig set
list price per year aimovig
first anti-cgrp product approv fda
approv inject set price
track commerci progress amgen/novarti aimovig erenumab
compani report clinicaltri gov canaccord genuiti estim updat
top-line result long term extens phase assess drug signal one
year troriluzol
initi second random control phase trial troriluzol
initi phase trial troriluzol
result potenti busi updat
potenti nda file rimegep
initi phase trial
initi phase trial
potenti approv sublingu riluzol al
futil analysi phase trial troriluzol mild moder
top-line data phase trial
potenti enrol complet trial troriluzol ocd
end
potenti enrol complet trial troriluzol gad
end
addit data rimegep zydi oral dissolv tablet studi
potenti top-line data phase trial rimegep prevent
potenti enrol complet trial troriluzol sca
complet addit toxicolog phase trial
estim studi complet date phase trial troriluzol
acut treatment
acut treatment
mild moder
acut treatment
acut treatment
mild moder
estim primari complet date estim
announc receiv fda may
proceed letter phase trial
announc fda accept
nda file treatment al action
date
initi trial phase trial success
announc enrol first patient
trial estim studi complet date
estim studi complet date phase trial troriluzol
potenti launch rimegep
updat eu strategi rimegep
result long-term safeti studi rimegep
addit data phase studi rimegep studi
addit data proof concept trial anxieti
potenti updat on-going phase trial
potenti nda file allergan ubrogep
result phase fortitude- trial reldesemtiv
later
potenti phase trial initi atogep chronic migrain
estim studi complet date phase trial amylyx
potenti nda approv lilli lasmiditan
top-lin result phase studi brainstorm cell
potenti data phase trial
potenti initi phase trial genervon
acut treatment
acut treatment
acut treatment
acut treatment
acut treatment
prevent migrain
acut treatment
acut treatment
receiv feedback ema outlin
sever potenti pathway approv rimegep per
file updat
announc initi result open-label
long-term safeti studi rimegep estim primari
complet date estim studi complet date
upcom scientif meet report
posit top-lin result trial
announc dose first patient
suffici fund oper per file
announc submiss nda
lasmiditan us fda
result avail year end present
medic confer
estim studi complet date phase trial allergan atogep
daili
estim studi complet date phase trial allergan atogep
daili
potenti launch allergan ubrogep
potenti launch allergan atogep
discuss european medicin agenc path forward
launch ramp teva ajovi fremanezumab
acut treatment
launch ramp lilli emgal galcanezumab
track commerci progress amgen/novarti aimovig erenumab
updat phase trial prana biotech
perform itf pharma tiglutik riluzol oral suspens
initi phase trial ibudilast
conduct addit analys data phase studi neuraltu
compani report clinicaltri gov canaccord genuiti estim updat
teva receiv approv price product
aimovig emgal
other monthli
lilli receiv approv price product
aimovig teva ajovi
receiv approv aimovig set
list price per year aimovig
first anti-cgrp product approv fda
approv inject set price
itf pharma receiv approv expect
launch
receiv posit feedback fda
phase plan ibudilast al
potenti accept nda vumer fda
potenti initi confirmatori phase studi
estim studi complet date phase trial
potenti initi phase trial
potenti result pivot phase trial passport
vixotrigin initi phase program trigemin neuralgia
end
potenti interim analys phase data aducanumab
potenti initi phase trial
potenti data phase trial
potenti exercis option acquir
potenti approv biosimilar adalimumab us
updat phase studi al
potenti five new asset enter clinic
potenti updat phase trial
potenti approv launch vumer
final data phase trial aducanumab
full data phase studi
end
sclerosi
alks/biib announc submiss nda
diroximel fumar regulatori pathway
identifi alkerm announc
receiv payment review
potenti file data posit
enrol phase studi small fiber neuropathi per
announc enter
exclus option agreement acquir tm co ltd japan
per slide ioni present date
exercis option ioni develop
commerci base posit interim data readout
phase trial plan add addit cohort
studi potenti support registr
biib/samsung bioepi announc accept
bla adalimumab biosimilar fda
asset acquir
estim studi primari complet date
estim studi complet date phase trial passport
estim studi complet date phase trial
identifi announc
enrol complet trial
associ
estim studi complet date phase affin trial
data phase affin studi opicinumab
estim studi complet date phase trial natalizumab
estim studi complet date phase trial tysabri
clinicaltri gov identifi
announc enrol first patient studi
top-lin result phase trial
estim studi complet date phase trial eisai
estim studi complet date phase trial eisai
estim studi complet date phase trial
estim studi complet date phase spirit trial
estim studi complet date phase trial
estim studi complet date phase trial engag
estim studi complet date phase trial emerg
estim studi complet date phase studi
estim studi complet date phase trial
estim studi complet date phase evolv studi
studi design assess clinic relev
updat biogen/univers pennsylvania sma gene therapi program
updates/furth detail phase studi alzheim
potenti initi phase studi evalu whether earli use
aducanumab prevent delay clinic onset ad
earn call said fda place ind
clinic hold updat call
eisai/biib present fuller data aaic meet chicago
ctad barcelona sub-group analys
present initi posit top-lin data
studi includ patient evid amyloid
patholog brain without subject cognit
complaint otherwis refer stage fda
draft guidanc treatment earli alzheim diseas
detail data phase trial dapirolizumab pegol upcom medic
potenti updat phase studi healthi volunt
impact roch ocrevu multipl sclerosi franchis
potenti busi develop activity/acquisit
novartis/avexi initi pediatr comer sma type
multi-n trial reach zolgensma
data novartis/avexi zolgensma pre-symptomat sma
type multi-n trial
complet novartis/avexi sma type phase trial strong
potenti approv launch novartis/avexi zolgensma
potenti approv launch novartis/avexi zolgensma
top-lin result phase studi firdaps
sma type
potenti approv launch novartis/avexi zolgensma
estim studi complet date phase trial aztherapi
estim studi complet date novartis/avexi zolgensma avxs-
type
type
earn press releas date biogen
announc acquir alg-
alivegen inc
receiv royalti ocrevu
enrol approxim patient six month
year age qualifi trial
time gene therapi
american academi neurolog annual meet
american academi neurolog annual meet
novarti announc fda accept nda
file prioriti review
novarti initi submiss mid-septemb anticip
complet file end
novarti submit ema earli
potenti studi complet novarti branaplam phase studi
potenti studi complet phase trial asclepio novarti
potenti studi complet phase trial asclepio ii novarti
potenti approv merck kgaa nda mavenclad cladribin
updat potenti submiss market author applic
shanghai greenvalley pharmaceut china
estim studi complet date phase trial
potenti studi complet phase trial sakura novarti
estim studi complet date roche/ptct
sma type
estim studi complet date phase trial roch gantenerumab
estim studi complet date roche/ptct
sma type
estim studi complet date novartis/avexi zolgensma avxs-
mild moder
mild moder
type
type
estim studi complet date trial
estim studi complet date phase trial solanezumab
estim studi complet date phase trial roch
prodrom mild ad
estim studi complet date phase trial roch gantenerumab
estim studi complet date phase trial roch gantenerumab
estim studi complet date novartis/avexi zolgensma avxs-
pre-symptomat sma type multi-n trial sprint
type
estim studi complet date phase trial novarti
fda accept nda merck kgaa mavenclad
patient enrol enrol approxim
patient copi less
six week age pre-symptomat time gene
estim studi complet date phase trial novarti
updat on-going pivot trial roch s/ptct
sma type
effect generic copaxon brand ms product
potenti path forward sma type
compani report clinicaltri gov canaccord genuiti estim updat
type
type
result potenti busi updat
potenti present data american societi
initi phase studi checkpoint inhibitor
initi phase poc studi
potenti data readout bridg bioavail ba pk studi
preliminari data readout phase poc studi
data phase poc studi
potenti ex-u partner japan
initi registr trial
data phase poc studi
potenti nda file
select next clinic candid
initi registr trial
potenti nda file
agit alzheim
diseas schizophrenia
agit alzheim
diseas schizophrenia
agit alzheim
diseas schizophrenia
agit alzheim
diseas schizophrenia
pancreat cancer
pancreat cancer
neoadjuv proof mechan trial initi
announc dose first six patient
studi expect enrol healthi adult volunt
expect complet dose patient
singl agent combo trial
mechan action combo trial
last least month
file
estim studi complet date phase trial avanir
estim studi complet date phase trial avanir
interim efficaci analysi axsom phase trial
top-lin result axsom phase trial
estim studi complet date phase trial avanir
estim studi complet date phase trial lundbeck
updat agit patient probabl alzheim diseas
program lumateperon
compani report clinicaltri gov canaccord genuiti estim updat
agit alzheim
agit alzheim
agit alzheim
agit alzheim
agit alzheim
agit alzheim
treatment agit
patient probabl
announc posit data interim
futil analysi phase trial
announc stop studi
futil
estim primari complet date estim
expect complet patient enrol
estim primari complet date estim
potenti adcom meet ahead fda action date
announc complet submiss nda
lumateperon treatment schizophrenia fda
announc accept nda fda
announc posit top-line data phase
studi patient parkinson diseas
result potenti busi updat
expect top line data phase trial lumateperon
expect top line data phase trial lumateperon
potenti fda advisori committe meet lumateperon
lumateperon action date pdufa schizophrenia
potenti file nda lumateperon bipolar depress
estim studi complet date phase trial
initi phase clinic trial
initi clinic trial
potenti initi clinic program lumateperon depress
expect top line data phase trial lumateperon
adjunct therapi lithium valproat
updat agit patient probabl alzheim diseas
program lumateperon
opioid substanc
use disord pain
potenti data open-label long-term safeti switch studi
initi phase trial restorbio combin rapalog
parkinson diseas
end
treatment agit
patient probabl
last per file
estim primari complet date estim
announc stop studi
futil
announc favor result
second part open-label safeti switch studi studi
data readout part open-label portion phase trial
bipolar depress
potenti snda approv allergan vraylar cariprazin
top-line result phase trial minerva mdd
top-line result allergan rapastinel phase trial
initi phase trial acadia pimavanserin adjunct therapi
potenti file nda schizophrenia
estim studi complet date allergan phase trial
estim studi complet date phase trial
potenti launch allergan vraylar cariprazin
potenti updat next step
result two phase trial minerva seltorex
patient mdd adjunct therapi
compani report clinicaltri gov canaccord genuiti estim updat
announc accept snda fda
pdufa action date may
form us fda nda plan
meet fda discuss content
potenti next step
data phase studi adult
potenti close transact
potenti nda file opicapon
potenti meet fda discuss result phase studi
adult
long-term data vy-aadc phase cohort
provid long-term data phase trial vy-aadc includ
data patient dose posterior-trajectori method
potenti initi phase studi pediatr
potenti supplement nda file elagolix
potenti initi pivot phase trial adult
top-lin data t-forc platinum studi ingrezza
estim studi complet date phase cohort trial
potenti updat phase trial novel inhibitor
select lead clinic candid friedreich ataxia program
collabor
enrol pivot phase begin vy-aadc
estim studi complet date phase open-label t-forc gold
trial pediatr patient ingrezza
potenti opicapon launch us
potenti complet phase enrol vy-
compani expand studi includ addit
patient optim dose flexibl conveni
updat patient cohort reach two
year sinc treatment enter
collabor agreement develop vy-aadc vy-
two addit program yet
receiv mileston royalti approv
month enrol complet month
announc first patient dose phase
clinicaltri gov identifi month
recruit patient trial
potenti data readout phase program vy-
data pivot phase studi phase extens studi
data analysi phase trial t-forc gold ingrezza
long-term data vy-aadc phase cohort
enrol statu phase trial vy-aadc
estim studi complet date phase trial pk/pd spruce
initi larger clinic studi emalex bioscienc ecopipam
potenti initi phase trial obseva linzagolix
initi data first two patient axov scienc phase dose
escal studi sunrise-pd axo-lenti-pd
potenti top-lin data phase trial lundbeck/prexton foliglurax
potenti data myovant/takeda phase liberti trial relugolix
top-line data intec pharma ap-cd/ld phase studi
estim studi complet date phase trial safeti efficaci
estim studi complet date phase trial artist teva
potenti data myovant/takeda phase liberti trial relugolix
start registr trial dipraglur
potenti data phase studi primros
potenti nda file myovant/takeda relugolix
estim studi complet date phase trial
potenti data myovant/takeda phase trial spirit
potenti initi clinic trial
announc phase t-forc gold
studi valbenazin pediatr tourett syndrom fail
last least next month per file
axon announc patient dose trial
estim studi complet date phase trial diurnal chronocort
estim studi complet date phase trial
top-line result therapix bioscienc phase trial
estim studi complet date phase trial impax
estim studi complet date phase trial bayer vilaprisan
updat allergan uliprist acet
compani report clinicaltri gov canaccord genuiti estim updat
allergan receiv complet respons letter
us fda abl approv uliprist acet
nda current form allergan plan meet fda
discuss comment next step
announc fda extend zulresso
pdufa date final rem
approxim patient recruit
approxim patient recruit
nda approv post-dea drug enforc
result potenti busi updat
data readout phase target engag studi
data readout phase multipl ascend dose trial
data readout phase singl ascend dose trial
data readout phase target engag studi
data readout phase multipl ascend dose trial
data readout phase singl ascend dose trial
initi phase open-label studi patient essenti
data readout part open-label portion phase trial
bipolar depress
initi phase multipl ascend dose trial patient
earli manifest huntington diseas
potenti launch zulresso brexanolon iv approv
top-line result phase open-label studi essenti
top-line result phase open-label studi patient
estim studi complet date phase mountain trial sage-
mdd
plan meet fda develop path
potenti updat addit scientif advic european medicin
agenc brexanolon
estim studi complet date phase rainforest trial sage-
mdd patient co-morbid insomnia
data phase mountain studi mdd
data phase rainforest studi mdd patient
data long-term retreat phase studi shorelin
top-line result allergan rapastinel phase trial
last per file
potenti snda approv allergan vraylar cariprazin
initi phase trial acadia pimavanserin adjunct therapi
top-line result phase trial minerva mdd
data part phase magnolia studi marinu
full data phase amarylli studi
expect top line data phase trial
expect top line data phase trial
top-lin result phase trial vistagen
estim studi complet date allergan phase trial
potenti file nda lumateperon bipolar depress
potenti launch allergan vraylar cariprazin
axsom meet fda discuss potenti regulatori path forward
result two phase trial minerva seltorex
patient mdd adjunct therapi
potenti approv janssen esketamin nasal spray us fda
result phase trial minerva seltorex patient
insomnia disord monotherapi
potenti launch rapastinel
potenti updat next step
announc accept snda fda
pdufa action date may
announc posit result part
announc posit result interim
analysi amarylli studi
expect complet patient enrol
estim primari complet date estim
estim primari complet date estim
form us fda nda plan
meet fda discuss content
potenti next step
estim primari complet date estim
favor fda advisori committe
meet esketamin pdufa date
updat neuralstem
expect top line data phase trial lumateperon
adjunct therapi lithium valproat
compani report clinicaltri gov canaccord genuiti estim updat
result potenti busi updat
interim read-out phase simplic studi
updat formal guidanc receiv scientif advic
work parti sawp european medicin agenc ema
multi-region phase studi
updat clinic develop pathway azeliragon
compani report clinicaltri gov canaccord genuiti estim updat
later
last less month per file
result potenti busi updat
long-term data vy-aadc phase cohort
provid long-term data phase trial vy-aadc includ
month data patient dose posterior-trajectori method
estim studi complet date phase cohort trial vy-
progress research activ abbvie/tau program compani
identifi five antibodi inclus toward develop
advanc monogen form al toward
enrol pivot phase begin vy-aadc
potenti complet phase enrol vy-aadc
potenti data readout phase program vy-aadc
long-term data vy-aadc phase cohort
initi human studi
enrol statu phase trial vy-aadc
initi data first two patient axov scienc phase dose
escal studi sunrise-pd axo-lenti-pd
potenti initi clinic trial
compani report clinicaltri gov canaccord genuiti estim updat
al huntington
updat patient cohort reach two
month enrol complet month
announc first patient dose phase
clinicaltri gov identifi month
recruit patient trial
last per busi updat call host
axon announc patient dose trial
